Citations

Clear

705 citation(s) found for "Cooper, C B".

Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study
McNamara, Dennis M. , Cooper, Leslie, Arbel, Yaron, Bocchi, Edimar, Hamer, A. J. , Herdy, Artur Haddad , Kerneis, Mathieu, Liu, Peter P., Parker, Andrea B., Pocock, Stuart , Smith, Eldon R., Tang, W H Wilson, Torre-Amione, Guillermo, Tschöpe, Carsten , Group, ARCHER Study, Bocch, Edimar, Moreira, Maria da Consolação Vieira , Dytz, Eduardo, Neuenschwander, Fernando Carvalho , Silva, Luís Beck da, Pezel, Theo, Abtan, Jeremie, Puymirat, Étienne , Moravsky, Gil, Piltz, Xavier Alejandro, Orlev, Amir , Bhat, Pavan , Thomas, Georgia , Lin, David, Palmer, Brittany, Kerneis, Mathieu , Pocock, Stuart J , McNamara, Dennis M , Tschöpe, Carsten , Friedrich, Matthias G. , Arbel, Yaron , Bhimaraj, Arvind , Hamer, Andrew, Tang, W.H. Wilson , Torre‐Amione, Guillermo , Caramori, Paulo , Moura, Lídia Zytynski , Macedo, Ariane Vieira Scarlatelli , Albuquerque, Denílson Campos de , Beck-da-Silva, Luís , Lattuca, Benoît , Bouleti, Claire , Pezel, Théo , Abtan, Jérémie , Delmas, Clément , Huang, Florent , Roubille, François , Bochaton, Thomas , Piltz, Xavier, Zlotoff, Daniel A , Hofmeyer, Mark R. , Hamer, Andrew

Mayo Clinic

ESC Heart Failure | January 6, 2026 | Volume: 13 | Issue: 1 | Pages: No page available

10.1093/eschf/xvaf034 | PMID 41711722 Get It

Abstract Introduction Cannabidiol has been shown to exert significant anti-inflammatory effects and has demonstrated efficacy in murine models of autoimmune myocarditis, pericarditis, and heart failure. The ARCHER Study assessed whether a pharmaceutically produced cannabidiol formulation showed beneficial effects on cardiac magnetic resonance (CMR) endpoints known to predict prognosis in this patient population. Methods In a multicentre international double-blind placebo-controlled phase 2 study, we randomly assigned 109 patients within 10 days of CMR confirmed diagnosis of acute myocarditis to 12 weeks of pharmaceutically produced oral cannabidiol (active) or placebo. Dose was titrated up to 10 mg/kg of body weight twice daily. Primary endpoints were the difference in extracellular volume (ECV) and global longitudinal strain (GLS) measured by CMR at week 12. Other CMR endpoints included left-ventricular ejection fraction (LVEF), LV mass, intracellular volume (ICV), LV end-diastolic and end-systolic volumes (LVEDV, LVESV), and left-atrial end-systolic volume (LAESV). Results All randomized patients (56 active/53 placebo) completed the study with no loss to follow-up. Study drug appeared safe and well tolerated. Baseline mean ECV 38.9 ± 10.9 ml, GLS −15.3 ± 3.6%, and LVEF 60.6 ± 9.9% were consistent with mild to moderate myocarditis and predominantly intact LV function. Week 12 mean ECV was 33.6 ml in the active group and 37.3 ml in the placebo group, a difference of −3.7 ml, confidence interval (CI): −7.4 to 0.1; P = .0538; GLS was −16.0% in the active group and −15.9% in the placebo group, difference of −0.1, CI: −1.2 to 1.1; P = .90. Left ventricular mass was significantly reduced in the active group at 121.1 g compared to placebo 130.3 g, a difference of −9.2, CI: −16.4 to −2.1; P = .0117. In terms of remodelling, LAESV was significantly reduced in the active group (−8.1 ml; P = .0376) while the reduction in LVEDV failed to reach significance (−7.4 ml; P = .098). Conclusion In mild-to-moderate acute myocarditis, treatment with pharmaceutically manufactured cannabidiol was not associated with a statistically significant change in myocardial ECV or GLS, although a trend towards reduction in ECV was observed. In addition, improvement in other potential markers of myocardial recovery, including a significant reduction in LV mass, was seen in the active treatment group. Further investigation of the therapeutic potential of this therapy in inflammatory cardiac conditions is warranted.
Epigenomic study of the lower airway reveals COPD-associated methylation patterns and potential microbiota links
Cao, Sudan , Shrivastav, Abhishek, Bleecker, Eugene R., Madapoosi, Siddharth , Erb‐Downward, John R. , Zein, Joe , Howard, Timothy D. , Hawkins, Gregory A., Barjaktarević, Igor , Bowler, Russell, Barr, Robert, Comellas, Alejandro P. , Cooper, Christopher B. , Hansel, Nadia N. , Hastie, Annette T. , Kanner, Richard E. , Moore, Wendy C. , O’Neal, Wanda K. , Paine, Robert , Smith, Benjamin M. , Hoffman, Eric A. , Meyers, Deborah A. , Woodruff, Prescott G. , Christenson, Stephanie A. , Ortega, Victor E. , Cao, Shuo , Chen, Xianfeng , Barjaktarevic, Igor , Comellas, Alejandro P , Han, MeiLan King , Kim, Victor , Huang, Yvonne J , O'Neal, Wanda K , Hoffman, Eric A , Christenson, Stephanie A , Chen, Xianfeng, Couper, David , Kaner, Robert J. , Martínez, Fernando J. , Curtis, Jeffrey L.

Mayo Clinic

BMJ Open Respiratory Research | December 19, 2025 | Volume: 12 | Issue: 1 | Pages: e003572

10.1136/bmjresp-2025-003572 | PMID 41419234 Get It

Introduction Despite the identification of multiple susceptibility loci by genome-wide association studies (GWAS), considerable chronic obstructive pulmonary disease (COPD) heritability remains unexplained. Aim To identify interaction networks of airway epithelial cell DNA methylation in COPD and further explore potential correlations with airway bacterial composition, as potentially collective regulators of biological pathways influencing COPD severity. Methods Using DNA isolated from bronchial airway brushings of 67 ever-smokers (>20 pack-years) from the SubPopulations and InteRmediate Outcomes Measures in COPD Study (SPIROMICS), we assessed proportion of DNA methylation (β) by epigenome-wide association study (EWAS) and examined associations of differentially methylated CpG probes (DMPs) with risk for moderate-to-severe COPD (N=34) versus absent or mild COPD (N=33). We tested co-methylation modules generated by Weighted Correlation Network Analyses (WGCNA) for associations with moderate-to-severe COPD and with bacterial genus-level relative abundances (16S rRNA sequencing). Results EWAS-identified nominally significant DMPs enriched for lung function GWAS loci. Eigengenes in six WGCNA modules were associated with moderate-to-severe COPD (false discovery rate <0.05). Four of those modules were enriched for forced expiratory volume in 1 s/forced vital capacity GWAS loci, and five overlapped with DMPs from EWAS. Overlapping CpG loci in three COPD-associated modules were adjacent to mucin genes; one had 10 genes highly ranked by connectivity with MUC5B, including important pathway genes: B3GNT6 , DGKI and ITGA8 . CpGs in an independent COPD-associated module showed the most correlations with Rothia , with directionality suggestive of negative associations with moderate-severe COPD. Conclusions Bronchial epithelial DNA methylation modules enriched for lung function GWAS loci associate with COPD severity in SPIROMICS. Potential module relationships to bronchial bacterial composition require further validation.
Management of Cancer During Pregnancy: ASCO Guideline
Loren, Alison W. , Lacchetti, Christina , Amant, Frédéric , Carey, Lisa A. , Christian, Nicole , Clark, Caroline C. , Dizon, Don S. , Hudson, Melissa M. , Maués, Julia , Peterson, Erika, Prowell, Tatiana M. , Raab, Rachel, Saeed, Hina , Watson, Katie, Yadav, Siddhartha , Carey, Lisa A , Christian, Nicole , Clark, Caroline , Dizon, Don S , Henry, Melissa , Hudson, Melissa M , Maues, Julia , Prowell, Tatiana M , Rogers, Jane E , Sekeres, Mikkael A , Taylor, Jolyn S , Van Loon, Katherine , Wallace, W Hamish , Yadav, Siddhartha , Partridge, Ann H , Amant, Frederic , Cardonick, Elyce H. , Rogers, Jane E. , Sekeres, Mikkael A. , Loon, Katherine Van , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | December 11, 2025 | Volume: 44 | Issue: 3 | Pages: 200-251

10.1200/jco-25-02115 | PMID 41380115 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more. PURPOSE To provide guidance on the recommended management of cancer in pregnant patients. METHODS A multidisciplinary Expert Panel convened and conducted a systematic review of the literature. RESULTS The systematic review identified 450 eligible studies. Much of the evidence consisted of observational data, case series, and case reports. RECOMMENDATIONS Management of cancer during pregnancy should be grounded in a values-based informed-consent process outlining maternal and fetal risks and anticipated benefits. Diagnostic evaluation should follow the as low as reasonably achievable (ALARA) principle, with timing of diagnostic studies individualized based on urgency of cancer detection, potential dangers of delay, and the balance of risks to both the pregnant patient and her embryo or fetus. Due to significant risk of harm to the developing embryo and/or fetus, systemic therapy should be deferred until the second trimester. Methotrexate, hormonal therapies, human epidermal growth factor receptor 2–targeted agents, vascular endothelial growth factor and poly (ADP-ribose) polymerase inhibitors, antibody-drug conjugates, and all cellular therapies are contraindicated during pregnancy, regardless of gestational age. For patients who wish to continue their pregnancy, delivery should be planned at or after 37 weeks, with the final chemotherapy dose scheduled 2-4 weeks before birth. Referral to psychosocial support services is essential to address emotional and practical challenges, reduce distress, and support shared decision making. Additional information is available at www.asco.org/survivorship-guidelines .
(078) Efficacy of Sacral Neuromodulation in Men With Overactive Bladder: A Retrospective Single Surgeon Cohort
Rafetto, A, Lehner, K, Hashemi, M Bonakdar, Lozoya, A Guillen, Kohler, T, Cooper, M, Rafetto, A, Lehner, K, Hashemi, M Bonakdar, Lozoya, A Guillen, Kohler, T, Cooper, M

Mayo Clinic

The Journal of Sexual Medicine | December 9, 2025 | Volume: 22 | Issue: Supplement_4 | Pages: No page available

10.1093/jsxmed/qdaf320.078 Get It

Abstract Introduction Sacral neuromodulation (SNM) is an effective third line treatment for overactive bladder (OAB). It is estimated that 10-27% of men suffer from OAB, however, prior studies on SNM have only reported on female-predominant cohorts. OAB in the male patient has gender-specific complexity given the effects of prostatic anatomy and associated therapeutics on voiding function, which may influence treatment outcomes and underutilization of SNM in this population. Objective We sought to assess a dedicated cohort of male patients undergoing SNM for refractory OAB by a single surgeon at our institution. Methods A retrospective cohort study was conducted, analyzing medical records of male patients who underwent SNM implantation for OAB by a single surgeon between February 2023 and September 2024. Data extraction encompassed demographic characteristics, urological history, and micturition parameters. The latter were assessed by using validated bladder diaries completed pre- and post-SNM implantation. Comparative analysis was conducted using independent t-tests and chi-square tests. Results Over the study period, 39 patients underwent either a peripheral nerve evaluation (PNE) or first stage SNM procedure, of which 32 (82.1%) had greater than 50% improvement in symptoms and underwent second stage implantation. 97.4% of the cohort had previously failed OAB medications, 25.6% had previously undergone bladder Botox, and 15.4% had previously undergone percutaneous tibial nerve stimulation. 30.8% had undergone a previous bladder outlet procedure (Table 1). In the cohort that underwent second stage implantation, average total voids in 24 hours improved from a median of 20.9 to 10.3 (Table 2, p&lt;0.001), daily leakage episodes improved from 3.9 to 1.3 (p=0.001) and pad usage improved by &gt;50%. Conclusions In this exploratory cohort, SNM demonstrated safety and efficacy in improving symptoms and quality of life for men with treatment-refractory OAB. Disclosure No
Determination of Adult Critical Care Physician Core Knowledge and Skills: Results of a Multidisciplinary, Modified Delphi Process
Tisherman, Samuel A. , Spevetz, Antoinette, Farmer, Joseph C. , Michener, Ed, Sreedharan, Roshni , Strickler, Samantha , Cuschieri, Joseph , Ellender, Timothy J., Kaups, Krista L. , Keegan, Mark T. , Lee, May M. , Malaiyandi, Deepa , Michetti, Christopher P. , Mohr, Nicholas M. , Moitra, Vivek K. , O’Neil, Kevin , Palmieri, Tina L. , Park, Pauline K., Raksin, P B , Shapshak, Angela Hays , Siddiqui, Shahla , Stein, Deborah M. , Timmons, Shelly D. , Vespa, Paul , Wessman, Brian T. , Wittwer, Erica D. , Medicine, on behalf of the Adult Critical Care Physician Core Knowledge and Skills Task Force of the Society of Critical Care, Farmer, J Christopher, Mohr, Nicholas M , Kashyap, Rahul , Leichtle, Stefan W. , Chang, Cherylee W. J. , Yataco, Angel Coz , Dudzinski, David M. , Emlet, Lillian L. , Fahy, Brenda G. , Geller, Bram J. , Hennessey, Erin , Park, Pauline K. , Pathak, Abhijit S. , Medicine, on behalf of the Adult Critical Care Physician Core Knowledge and Skills Task Force of the Society of Critical Care, Siddiqui, Shahla

Mayo Clinic

Critical Care Medicine | December 9, 2025 | Volume: 54 | Issue: 2 | Pages: 224-233

10.1097/ccm.0000000000006978 | PMID 41363909 Get It

Objectives: In the United States, training for physicians who manage critically ill adult patients (intensivists) evolved through parallel subspecialty critical care medicine (CCM) pathways with significant commonality. The Society of Critical Care Medicine Adult Critical Care Physician Core Knowledge and Skills Task Force aimed to delineate the common core knowledge and skills required of all intensivists. Design: A master list of content areas and procedural skills was compiled from all CCM subspecialty program requirements and blueprints of the certification examinations. Using a modified Delphi approach, participants were asked to categorize the knowledge items as “advanced knowledge is essential,” “general, but not advanced, knowledge is essential,” or “knowledge is not essential.” Procedures were categorized as “intensivist performs routinely,” “intensivist only performs in an emergency,” or “intensivist knows” about the procedure. Setting: Representatives from CCM stakeholder organizations, including accreditation and certification organizations, critical care societies, and program directors’ societies, were invited to participate. SUBJECTS: Members of the Adult Critical Care Physician Core Knowledge and Skills Task Force of the Society of Critical Care Medicine. Interventions: For the first two rounds of the modified Delphi process, Research Electronic Data Capture was used. For the third and fourth rounds, the process was completed through online meetings with Zoom (Zoom Video Corporations, San Jose, CA) utilizing Zoom’s polling feature. Measurements and Main Results: A total of 541 items were determined to be essential, with 145 requiring advanced knowledge and 323 requiring general knowledge. For 73 items, consensus regarding advanced vs. general could not be achieved, but they remained essential. Only eight items were felt to be nonessential. Of the 16 procedures, most were categorized as “intensivist performs.” Conclusions: The large number of items included in the list of essential knowledge and skills demonstrates the complexity of modern CCM. Utilization of a common framework across the subspecialties of CCM could lead to greater harmonization among the fellowship program requirements and certification examinations.
Artificial Intelligence-Based Predictive Modeling for Early Detection of Sepsis in Hospitalized Patients: A Systematic Review and Meta-Analysis
Abbas, Ghulam , Sen, Palash, Giri, Oviya Anjali , Khan, Nawaid Hussain , Sen, Palash

Mayo Clinic

Critical Care Explorations | December 5, 2025 | Volume: 7 | Issue: 12 | Pages: e1360

10.1097/cce.0000000000001360 | PMID 41348160 Get It

OBJECTIVES: This systematic review evaluates artificial intelligence (AI)-based predictive models developed for early sepsis detection in adult hospitalized patients. It explores model types, input features, validation strategies, performance metrics, clinical integration, and implementation challenges. DATA SOURCES: A systematic search was conducted across PubMed, Scopus, Web of Science, Google Scholar, and CENTRAL for studies published between January 2015 and March 2025. STUDY SELECTION: Eligible studies included those developing or validating AI models for adult inpatient sepsis prediction using electronic health record data and reporting at least one performance metric (area under the curve [AUC], sensitivity, specificity, or F1 score). Studies focusing on pediatric populations, lacking quantitative evaluation, or unpublished in peer-reviewed journals were excluded. DATA EXTRACTION: Data extraction followed preferred reporting items for systematic reviews and meta-analyses guidelines. Extracted variables included study design, patient population, model type, input features, validation approach, and performance outcomes. DATA SYNTHESIS: A total of 52 studies met the inclusion criteria. Most used retrospective designs, with limited prospective or real-time clinical validation. Commonly used algorithms included random forests, neural networks, support vector machines, and deep learning architectures (long short-term memory, convolutional neural network). Input data varied from structured sources (vital signs, laboratory values, demographics) to unstructured clinical notes processed via natural language processing. Reported AUC values ranged from 0.79 to 0.96, indicating strong predictive performance across models. CONCLUSIONS: AI models demonstrate significant promise for early sepsis detection, outperforming conventional scoring systems in many cases. However, generalizability, interpretability, and clinical implementation remain major challenges. Future research should emphasize externally validated, explainable, and scalable AI solutions integrated into real-time clinical workflows.
A plain language summary of patient preferences for treatments for multiple myeloma that has relapsed or is refractory to prior therapy
Mansfield, Carol , Bussberg, Cooper , Chi, Lei, Kroog, Glenn S. , Rodriguez-Lorenc, Karen, Ahlstrom, Jenny, Ma, Qiufei , Ailawadhi, Sikander , Inocencio, Timothy J. , Chintakayala, Phani , Harnett, James

Mayo Clinic

Future Oncology | December 1, 2025 | Volume: 21 | Issue: 29 | Pages: 3701-3711

10.1080/14796694.2025.2584284 | PMID 41324502 Get It

Personalized Acute Upper GI Bleeding Diagnostics for Patients at Highest Risk for Endoscopy: Real-World Experience of a Novel, Binary, Bedside Gastric Blood Detection Device
Aggarwal, Manik , Hamlin, Miranda M. , Akiki, Karl, Abou Zeid, Hadi Khaled, AbiMansour, Jad P. , Hamlin, Miranda , Zeid, Hadi Khaled Abou , Salameh, Yara , Storm, Andrew C.

Mayo Clinic

Journal of Personalized Medicine | November 28, 2025 | Volume: 15 | Issue: 12 | Pages: 573

10.3390/jpm15120573 | PMID 41440936 Get It

Background: Upper gastrointestinal bleeding (UGIB) is a common medical emergency associated with significant morbidity, mortality, and healthcare costs. Many patients undergo early endoscopy despite the absence of active bleeding. PillSense is a novel Food and Drug Administration (FDA)-cleared ingestible capsule that rapidly detects the presence of blood in the upper GI tract and may optimize triage decisions. Methods: We conducted a retrospective study evaluating the impact of PillSense on the management of suspected UGIB in an academic center. The primary outcome was the association between capsule results and clinical decision-making, including endoscopy deferral, prioritization, outpatient scheduling, and airway protection. Secondary outcomes included transfusion requirements, time-to-endoscopy, endoscopic intervention, and 30-day adverse events. Results: A total of 28 patients (mean age 64.4 ± 17.9 years, 82.7% male) were included. Compared with negative results, positive results were associated with higher transfusion requirements (median 3 (IQR 3–6) vs. 2 (IQR 1–3.25) units; p = 0.041) and shorter time-to-endoscopy (median 0.2 (IQR 0.01–1) vs. 2 (IQR 1–15.5) days; p = 0.017). In high-risk for sedated endoscopy patients, negative results were associated with EGD deferral in 53.8%, with no subsequent adverse events within 30 days. Endoscopic intervention was performed in 62.5% of positive-result patients versus 9.5% of negative-result patients. Conclusions: The PillSense results were associated with differences in triage and management of high-risk patients with suspected UGIB. Its rapid, accurate, and non-invasive results may reduce unnecessary urgent endoscopy procedures, improve resource utilization, and enhance patient safety, particularly in the highest-risk populations.
Socioeconomic position and its effect on cardiovascular outcomes and mortality in patients with prostate cancer
Nahle, Tarek , Shah, Viraj , Kunhiraman, Harikrishnan Hyma , Afzal, Muhammad Umar , Riaz, Irbaz Bin , Agarwal, Neeraj , Swami, Umang , Rachoin, Jean-Sébastien , Weintraub, Neal L, Guha, Avirup , Makram, Omar M , Shah, Viraj R , Hyma Kunhiraman, Harikrishnan , Afzal, Muhammad Umar , Riaz, Irbaz B , Agarwal, Archana M , Swami, Umang , Rachoin, Jean-Sebastien , Guha, Avirup

Mayo Clinic

JNCI Cancer Spectrum | November 26, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/jncics/pkaf113 | PMID 41308174 Get It

Abstract Background Socioeconomic position (SEP) is a fundamental social determinant of health (SDoH) contributing to observed disparities in cancer and cardiovascular (CV) care among individuals with prostate cancer (PC). Understanding the influence of SEP on CV health is essential for addressing outcome inequities within this population. Methods We conducted a retrospective study utilizing Surveillance, Epidemiology, and End Results (SEER)-Medicare to evaluate CV outcomes in patients ≥65 years with PC from 2009 to 2017. We studied the impact of SEP on cardiovascular events (CVEs), cardiovascular mortality (CVm), PC-specific mortality (PCsm), and all-cause mortality. CVE, CVm, and PCsm were analyzed using competing risk models and all-cause mortality with Cox proportional hazards models. A subgroup analysis was performed in Non-Hispanic Black and Non-Hispanic White individuals. Results We included 141 242 patients of whom 76 844 were in high SEP areas (45.6%) and 64 398 in low SEP ones (54.4%). Both groups had a mean age of 72 years; patients in low SEP areas were 67.5% Non-Hispanic White, 34.4% having diabetes, 73.3% hypertension, and 67.7% dyslipidemia versus the high SEP group with 85.6% Non-Hispanic White, 30.4% diabetes, 69.9% hypertension, and 70.7% dyslipidemia. Patients in low SEP areas had higher risks of CVm (subdistribution hazard ratio [sHR] = 1.18, 95% CI = 1.12 to 1.25), PCsm (sHR = 1.12, 95% CI = 1.06 to 1.17), CVE (sHR = 1.07, 95% CI = 1.04 to 1.09), and all-cause mortality (HR 1.16, 95% CI = 1.13 to 1.20). Accentuated results were shown in the Non-Hispanic Black subgroup. Conclusion Adverse SEP plays a significant role in shaping outcomes among older patients with PC, contributing to elevated risks of adverse CV and survival outcomes.
Meniscal Repair in the Setting of Revision Anterior Cruciate Ligament Reconstruction: 6-Year Follow-up Results From the MARS Cohort
Group;, MARS, Fox, Jake A. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Col. Steven J., Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Williams, James S., Wolcott, Michelle L., York, James J. , Wright, Rick W. , Svoboda, Steven J. , Group;, MARS, Pennings, Jacquelyn S. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J., Brophy, Robert H. , Carpenter, James E., Cox, Charles L. , David, Tal S. , Flanigan, David C. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , Marx, Robert G. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Sherman, Orrin H. , Spang, Jeffrey T. , Vidal, Armando F. , Wolf, Brian R.

Mayo Clinic

The American Journal of Sports Medicine | November 12, 2025 | Volume: 53 | Issue: 14 | Pages: 3435-3445

10.1177/03635465251387333 | PMID 41220248 Get It

Background: Meniscal preservation has been demonstrated to contribute to long-term knee health and has been a successful intervention in isolation and in patients with anterior cruciate ligament reconstruction (ACLR). The long-term results of meniscal repair in the setting of revision ACLR have yet to be documented. Purpose: To report the incidence of meniscal repair failures at the 6-year follow-up in a cohort of patients who underwent concurrent revision ACLR and primary meniscal repair. Study Design: Prospective cohort study; Level of evidence, 2. Methods: All revision ACLRs with concomitant primary meniscal repair cases from a multicenter group between 2006 and 2011 were selected. Six-year follow-up was obtained to determine whether any subsequent surgery had occurred since their initial revision ACLR. If so, operative reports were obtained, whenever possible, to verify pathological condition and treatment. Results: In total, 221 patients from 1234 revision ACLRs underwent concurrent primary meniscal repairs (18% of the cohort). There were 238 repairs performed: 173 medial and 65 lateral. The majority of these repairs (n = 181; 76%) were performed with an all-inside technique. Six-year surgical follow-up was obtained in 77% (171/221) of the cohort, or 189 of 238 (79%) of the repairs (136 medial, 53 lateral). The meniscal repair failure rate, defined as reoperation, was 16% (31/189) at 6 years. Of the 31 failures, 28 were medial (24 all-inside, 4 inside-out; 28/136 = 20.6% failure rate) and 3 were lateral (2 all-inside, 1 inside-out; 3/53 = 5.7% failure rate). Three medial failures were treated in conjunction with a subsequent repeat revision ACLR. Medial tears underwent reoperation for failure at a significantly higher rate than lateral tears (20.6% vs 5.7%; P = .01) and had a significantly shorter survival time compared with lateral tears ( P = .02). No difference was found between the failure and nonfailure groups when it came to tear type, tear length, repair technique utilized, suture/implant type, or number of sutures used between the 2 groups. Conclusion: Meniscal repair in the revision ACLR setting has a 16% failure rate at 6 years. Failure rates for medial tears (20.6%) were found to be higher than that for lateral tears (5.7%), which aligns with previous studies in both the revision and primary ACLR setting.